Concord Biotech Ltd Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CONCORD BIOTECH LTD
CONCORD BIOTECH LTD has five approved drugs.
Summary for Concord Biotech Ltd
| US Patents: | 0 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 5 |
| Drug Master File Entries: | 16 |
Drugs and US Patents for Concord Biotech Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concord Biotech Ltd | TACROLIMUS | tacrolimus | CAPSULE;ORAL | 213112-002 | Nov 10, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Concord Biotech Ltd | TERIFLUNOMIDE | teriflunomide | TABLET;ORAL | 218663-002 | Apr 7, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Concord Biotech Ltd | TACROLIMUS | tacrolimus | CAPSULE;ORAL | 213112-001 | Nov 10, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Concord Biotech Ltd | MYCOPHENOLATE SODIUM | mycophenolate sodium | TABLET, DELAYED RELEASE;ORAL | 211173-001 | Dec 13, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Concord Biotech Ltd | TACROLIMUS | tacrolimus | CAPSULE;ORAL | 213112-003 | Nov 10, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

